Immuno-Oncology

Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.

Relatlimab plus nivolumab and chemotherapy did not improve responses in untreated advanced gastric or GEJ cancer with a LAG-3 expression of at least 1%.

Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.

First-line treatment with the combination of Versamune HPV and pembrolizumab met a best overall response end point in recurrent/metastatic HNSCC.

Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.

Frontline pembrolizumab plus trastuzumab/chemotherapy improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.

The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.

Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.

Experts highlight clinical trial updates in muscle-invasive bladder cancer, frontline treatment options in metastatic urothelial carcinoma, and more.

Exploration continues for the use of immunotherapy in patients with mismatch repair–proficient endometrial cancer.

Adjuvant nivolumab extended DFS, NUTRFS, and DMFS vs placebo and showed for the first time an improvement in OS in patients with high-risk muscle-invasive urothelial cancer.

Durvalumab plus chemotherapy produced superior 3-year survival outcomes vs chemotherapy alone in advanced biliary tract cancer.

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.

The new drug application for sintilimab plus fruquintinib has been granted priority review by the NMPA for pMMR/non-MSI-H advanced endometrial cancer.

Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.

The incorporation of immune checkpoint inhibitors has altered the treatment paradigm for endometrial cancer.

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts explain the challenges faced with preventing or detecting these cancers early and the understanding needed to develop effective early detection methods and move the needle forward.

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.

The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.

Pembrolizumab plus olaparib as first-line maintenance therapy did not improve survival in patients with metastatic nonsquamous non–small cell lung cancer.

Improved overall survival was achieved with nivolumab plus ipilimumab vs standard-of-care TKIs in patients with advanced hepatocellular carcinoma.

Michael J. Overman, MD, discusses the potential advantages of using nonoperative immunotherapy-based approaches in select gastrointestinal cancers.

Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.

Adjuvant nivolumab significantly improved relapse-free survival vs ipilimumab in resected stage III/IV melanoma, according to 7-year minimum follow-up.

The FDA and EMA have accepted applications seeking the approval of neoadjuvant nivolumab/chemotherapy followed by surgery and adjuvant nivolumab in NSCLC.

Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study.